Profile & Biography of Dr Andre Kalil
| Real Name: | Dr Andre Kalil |
| Age: | 50-55 yrs |
| Birthplace: | United States Of America
|
| Profession: |
Medical Doctor
|
| Primary Practice Location: | Durham Outpatient Center Internal Medicine Specialties 4400 Emile St. Omaha, NE 68105 Phone: 402-559-8650 Fax: 402-559-5581 |
| Medical School: |
Universidade Federal de Pelotas
|
| Residency: |
Internal Medicine, University of Miami
|
| Fellowship: | Infectious Diseases, National Institutes of Health Critical Care Medicine, Massachusetts General Hospital |
Who Is Dr Andre Kalil
Meet Dr Andre Kalil he is a Professor, Department of Internal Medicine Director, Transplant Infectious Diseases. He is the medical doctor appointed to oversee the study at the University of Nebraska Medical Center for the first clinical trial in the U.S of a possible vaccine for treatment of coronavirus.
Dr Andre is an infectious disease specialist in Omaha, Nebraska. He is currently licensed to practice medicine in Nebraska. He is affiliated with Nebraska Medicine, Nebraska Medical Center and is an Associate Professor at University of Nebraska Medical Center College of Medicine.
Education & Qualifications Of Dr Andre Kalil
Dr Andre Kalil obtained his degree in Medicine from Universidade Federal de Pelotas
He is a student of Massachusetts General Hospital – Fellowship
National Institutes of Health Clinical Center – Fellowship
Jackson Memorial Hospital – Jackson Health System – Residency
Dr Andre Kalil Family
Not much is known about Dr Andre Kalil’s family and relations
Certification & License
Dr Andre Kalil got his certification & License From NE State Medical License in 2002 – 2020.
He is the a member of the American Board of Internal Medicine Infectious Disease.
Fellowship
Infectious Diseases, National Institutes of Health & Critical Care Medicine, Massachusetts General Hospital.
Board Certification
Infectious Diseases, American Board of Internal Medicine, Critical Care Medicine, American Board of Internal Medicine & Internal Medicine, American Board of Internal Medicine.
Dr Andre Kalil works with the Nebraska Medicine.
Professional Memberships
Dr Andre Kalili is a member of American College of Physicians – ACP
Clinical Rials
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections.
Start of enrollment: 2009 Jun 01
Hardiman, P.,Kalil, A.
Adaptive COVID-19 Treatment Trial
Dr Andre Kalil Publications & Presentations
Procalcitonin predicts the severity of cystic fibrosis pulmonary exacerbations and readmissions in adult patients: a prospective cohort study.
Bailey, K. L., Murphy, P. J., Lineberry, O. K., Haack, M. R., Dickinson, J. D., Kalil, A. C.> ;Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2020 Jan 24.
Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?
Kalil, A. C., Holubar, M., Deresinski, S., Chambers, H. F.> ;Antimicrobial agents and chemotherapy. 2019 Oct 24.
Dr Andre Kalil Involvement On Covid-19 Vaccine Treatment Trial
Dr. Andre Kalil, a key clinical trial researcher on remdesivir, says preliminary results “were so important … we decided this has to be out to the public,” despite not yet being peer-reviewed. https://t.co/y4pnSeOBz7 pic.twitter.com/Dlhk9oNKtT
— CNN (@CNN) April 30, 2020
The first clinical trial in the U.S. of a possible coronavirus treatment was initiated in Nebraska and eventually it was expected to include 400 patients at 50 locations around the world.
According to sources, half of the patients in the international study will receive the antiviral medicine remdesivir while the other half will receive a placebo. Several other studies, including one looking at the same drug, are already underway internationally.
Dr. Andre Kalil, was appointed to oversee the study at the University of Nebraska Medical Center.
While speaking on the possible vaccine for the treatment of Covid-19 said the clinical trial was developed quickly in response to the virus outbreak that originated in China.
Patients who are hospitalized with the COVID-19, the disease caused by the virus, will be eligible to join the trial if they have at least moderate symptoms.
